XenoGesis to Move Into BioCity Discovery Building

XenoGesis will be the next tenant to move into BioCity Nottingham’s state-of-the-art Discovery Building, with the support of grant funding from the Government’s Regional Growth Fund and the University of Derby Invest to Grow Program.

XenoGesis is an independent laboratory-based contract research organization specialized in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology and modeling & simulation for human PK and dose prediction. 

The company will be taking 5,500ft2 on the first floor of the Discovery Building which was officially opened in June 2017. The new space will provide an 83% increase on the existing laboratories and offices that XenoGesis occupies in the Innovation Building. 

XenoGesis is a BioCity success story, starting out with a team of three the business has now grown to 25 employees, expanding its laboratory space and investing in state-of-the-art equipment.

Chief executive of BioCity, Glenn Crocker, said: "Since starting out at BioCity, XenoGesis has gone from strength to strength. This expansion is yet more evidence of the success of this great company and, I’m sure, the start of a new phase of growth. We are proud to have XenoGesis as an active member of the BioCity community and to be an investor in this high-quality business."

Register as Visitor to CPhI China 2018!